Bristol-Myers Squibb and Alder Biopharmaceuticals, Inc. entered a global agreement for the development and commercialization of ALD518, a biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. Under the terms of the collaboration, BMS gains worldwide exclusive rights to develop and commercialize the drug for all potential indications except cancer, for which Alder will retain rights and BMS has an option to co-develop and commercialize outside the U.S. Al...